These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://anitadsts753059.slypage.com/39722617/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide